Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bevacizumab + bicalutamide + goserelin
- Development stage
- Unknown
- Lead developer
- Genentech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Peptides, Small Molecules
- Administration
- Intravenous, Oral, Subcutaneous
01
Overview
This combination therapy consists of bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor (VEGF), combined with bicalutamide, a small molecule antiandrogen, and goserelin, a peptide-based luteinizing hormone-releasing hormone (LHRH) agonist. The regimen was investigated in a Phase II clinical trial for patients with high-risk localized prostate cancer receiving intensity-modulated radiation therapy (IMRT). The rationale for this combination is to enhance the efficacy of standard long-term androgen suppression (LTAS) by adding anti-angiogenic therapy to inhibit tumor growth and progression mediated by VEGF signaling.
- Other names
- bevacizumab + bicalutamide + goserelin
02
Targets
GnRHR (Gonadotropin-releasing hormone receptor)VEGFA (Vascular endothelial growth factor A)AR (Adrenergic receptors)
Beyond the preview
Go deeper on bevacizumab + bicalutamide + goserelin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bevacizumab + bicalutamide + goserelin.